Stockscreener 앱 받기
47.46
1.04%
-0.50
시간 외 거래:
47.42
-0.04
-0.08%
전일 마감가:
$47.96
열려 있는:
$48.2
하루 거래량:
24.23M
Relative Volume:
0.64
시가총액:
$12.37B
수익:
$1.78B
순이익/손실:
$164.40M
주가수익비율:
68.78
EPS:
0.69
순현금흐름:
$236.51M
1주 성능:
+14.61%
1개월 성능:
-16.40%
6개월 성능:
+88.33%
1년 성능:
+123.76%
1일 변동 폭
$46.70
$48.20
1주일 범위
$40.88
$51.99
52주 변동 폭
$13.47
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
명칭
Hims Hers Health Inc
전화
415-851-0195
주소
2269 CHESTNUT ST, SAN FRANCISCO
HIMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
47.46 | 12.37B | 1.78B | 164.40M | 236.51M | 0.69 |
|
PG
Procter Gamble Co
|
161.20 | 381.79B | 83.93B | 15.50B | 15.03B | 6.30 |
|
UL
Unilever Plc Adr
|
61.39 | 154.84B | 65.10B | 6.16B | 0 | 2.4569 |
|
CL
Colgate Palmolive Co
|
92.40 | 74.51B | 19.95B | 2.90B | 3.47B | 3.54 |
|
KMB
Kimberly Clark Corp
|
132.36 | 44.14B | 19.75B | 2.47B | 2.39B | 7.34 |
|
KVUE
Kenvue Inc
|
20.90 | 41.32B | 15.30B | 1.06B | 1.45B | 0.55 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재확인 | Needham | Buy |
| 2025-04-29 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2025-01-07 | 개시 | BTIG Research | Buy |
| 2024-12-17 | 개시 | Morgan Stanley | Overweight |
| 2024-11-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-08-22 | 개시 | Needham | Buy |
| 2024-08-09 | 다운그레이드 | Imperial Capital | Outperform → In-line |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-04-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-10 | 개시 | Canaccord Genuity | Buy |
| 2024-02-28 | 업그레이드 | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2023-12-07 | 개시 | Imperial Capital | In-line |
| 2023-07-28 | 개시 | TD Cowen | Outperform |
| 2023-04-11 | 개시 | Robert W. Baird | Neutral |
| 2023-02-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-08 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-07-15 | 개시 | SVB Leerink | Underperform |
| 2022-04-14 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | Deutsche Bank | Hold |
| 2021-12-02 | 개시 | Jefferies | Hold |
| 2021-11-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 개시 | BofA Securities | Neutral |
| 2021-05-20 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 개시 | Truist | Hold |
| 2021-03-09 | 개시 | Credit Suisse | Neutral |
| 2021-03-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-02-17 | 개시 | Citigroup | Neutral |
| 2021-02-12 | 개시 | Piper Sandler | Neutral |
| 2021-02-08 | 개시 | Tigress Financial | Buy |
모두보기
Hims Hers Health Inc 주식(HIMS)의 최신 뉴스
Hims & Hers Goes Global, Named To Top Stocks List: Build Your Growth Stock Watchlist With These Just Updated Screens - Investor's Business Daily
Where Will Hims & Hers Stock Be In 10 Years? - Barchart.com
Hims & Hers Health Inc Stock: Navigating High Volatility and a Rich Valuation - Daily Chhattisgarh News
Bet on Winning DuPont Analysis & Pick 3 Top Stocks - Yahoo Finance
Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth) - Barchart.com
Hims & Hers Health Annual Stockholders Meeting Results - TipRanks
Hims & Hers (HIMS) Stock Pauses After Explosive 134% Rally This Year, Highlighting Immense Growth - Daily Chhattisgarh News
These 2 Growth Stocks Are No-Brainer Buys Right Now - Yahoo Finance
VF Corp, MGM Resorts, PENN Entertainment, Hims & Hers Health, and Camping World Shares Are Soaring, What You Need To Know - Yahoo Finance
2 Reasons To Double Down On Hims & Hers Ahead Of August (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Stock Skyrockets Over 8%, Extending a Phenomenal 147% Annual Gain - Daily Chhattisgarh News
Where are the Opportunities in (HIMS) - news.stocktradersdaily.com
Hims & Hers: An Excellent Subscription Business - Seeking Alpha
The controversial rise of Franken-pills: Telehealth companies push to mix meds in a single pill - Sherwood News
Hims & Hers (HIMS) Stock Dips Amid Profit-Taking, But Yearly Gains Exceed a Massive 134% - Daily Chhattisgarh News
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Hims & Hers Health and Sociedad Quimica y Minera de Chile have been highlighted as Zacks Bull and Bear of the Day - Zacks Investment Research
Where Will Hims & Hers Stock Be in 10 Years? - The Globe and Mail
Noteworthy Thursday Option Activity: PARR, VZ, HIMS - Nasdaq
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth - Yahoo Finance
Hims & Hers (HIMS) Share Price Shows Explosive Growth, Surging Over 150% in a Year - Daily Chhattisgarh News
June 2025's Select Stocks That Could Be Trading Below Estimated Value - simplywall.st
Hims & Hers Health’s (HIMS) Equal Weight Rating Reaffirmed at Morgan Stanley - Defense World
3 Reasons We Love Hims & Hers Health (HIMS) - Yahoo Finance
HIMS Experiences Mixed Growth in App Downloads and Web Traffic | - GuruFocus
Hims & Hers (HIMS) Stock Soars, Capping a Year of Explosive Growth - Daily Chhattisgarh News
Hims & Hers Stock Falls After Eli Lilly Rules Out Telehealth Tie-Up: Citi Calls It Aggressive Stance, Retail Turns Bearish - MSN
Hims & Hers: The ZAVA Acquisition Catapults Growth In Europe's Weight-Loss Market - Seeking Alpha
Lilly Pacts Bar Telehealth Firms From Selling Copycat Zepbound - MSN
Needham Lifts PT on Hims & Hers Health (HIMS) Stock, Maintains Buy Rating - MSN
Hims & Hers Health (NYSE:HIMS) Shares Down 1.8% on Insider Selling - Defense World
Citi Keeps Hims & Hers (HIMS) Price Target, Maintains Sell Rating - MSN
HIMS Faces Uncertain Future with Potential Eli Lilly Partnership - GuruFocus
Is Hims & Hers Health a Smart Buy Right Now? - MSN
Lilly Pacts Prohibit Telehealth Sales of Copycat Zepbound - Bloomberg.com
Hims & Hers stock falls after Lilly rules out partnership - Investing.com Australia
Lilly (LLY) Pacts Bar Telehealth Firms From Selling Copycat Zepbound - Bloomberg.com
Hims & Hers says its weight-loss business can grow as US market changes - Reuters
Bought $40,000 of Hims & Hers (HIMS) Stock on a YOLO – Is it Time to Sell? - AOL.com
Hims & Hers Health's Strategy in the Evolving Weight-Loss Drug MarketNews and Statistics - IndexBox
Hims & Hers (NYSE: HIMS) Live: Complete Earnings Coverage - AOL.com
Bought $40,000 of Hims & Hers (HIMS) Stock on a YOLOIs it Time to Sell? - 24/7 Wall St.
Hims & Hers (HIMS) Stock Stays Flat After Volatile Session, Highlighting Massive Yearly Gains - Daily Chhattisgarh News
Analysis: Hims & Hers says its weight-loss business can grow as US market changes - Yahoo Finance
Why Hims & Hers Health (HIMS) Might be Well Poised for a Surge - Yahoo Finance
Hims & Hers Health, Inc. (HIMS): A Bull Case Theory - Insider Monkey
Hims & Hers Health Unusual Options Activity - Nasdaq
Hims & Hers (HIMS) Stock Tumbles 10% in a Week, Pausing a Meteoric 160% Annual Rally - Daily Chhattisgarh News
Hims & Hers Health and AST SpaceMobile have been highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
Hims & Hers Health, Inc. (NYSE:HIMS) Receives Consensus Rating of “Hold” from Analysts - Defense World
Hims Hers Health Inc (HIMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Hims Hers Health Inc 주식 (HIMS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Okupe Oluyemi | Chief Financial Officer |
Jun 23 '25 |
Sale |
47.25 |
23,107 |
1,091,766 |
63,222 |
0.91%
0.33%
자본화:
|
볼륨(24시간):